RxDoctor Payments Data

Myo Win, MD

Internal Medicine · Melbourne, FLNPI 1841284858

Payments from drug & device makers

$5,196in general payments, 2019–2025

Across 291 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Boehringer Ingelheim$677
  • Exact Sciences$371
  • Lilly USA, LLC$339
  • AbbVie$293
  • Novo Nordisk$280
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$5,08098%
  • Education$1172%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,196 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$129,559
Medicare patients
260
Services billed
1,532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban37$46,169
JardianceEmpagliflozin26$43,497
FarxigaDapagliflozin Propanediol39$38,880
RybelsusSemaglutide11$27,860
OzempicSemaglutide19$23,375
XareltoRivaroxaban13$17,024
TrulicityDulaglutide13$15,821
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,919
GlyxambiEmpagliflozin/Linagliptin12$6,769
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$6,502
Levothyroxine Sodium438$6,068
Rosuvastatin Calcium349$5,927
Atorvastatin Calcium302$3,877
VascepaIcosapent Ethyl11$3,750
Albuterol Sulfate HfaAlbuterol Sulfate107$3,731

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$280$51,23530 claims
Boehringer IngelheimJardiance, Glyxambi$677$50,26638 claims
PfizerEliquis$250$46,16937 claims
AstraZenecaFarxiga$1,293$38,88039 claims
Johnson & JohnsonXarelto$138$17,02413 claims
Lilly USA, LLCTrulicity$339$15,82113 claims
GSKTrelegy Ellipta$260$7,91912 claims
AbbVieSynthroid$293$2,84540 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →